Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG Saturno, F Lopes, I Niculescu-Duvaz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2019
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNAL Tan, S Sandhu, R J Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2024
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncologyL Kandolf, P A Ascierto, L Bastholt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countriesL Kandolf Sekulovic, J Guo, S Agarwala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Pageof 7